TAXATION
Mutual Fund Distributions: How Capital Gain Distributions Are Taxed
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
Franklin Biotechnology Discovery R6
- FRBRX
- Price as of: Oct 23, 2020
-
$184.04
N/A N/A
- Primary Theme
- Health Care Sector Equity
- Fund Company
- Franklin Templeton
- Share Class
FRBRX - Snapshot
Vitals
- YTD Return 17.4%
- 3 Yr Annualized Return 8.4%
- 5 Yr Annualized Return 8.0%
- Net Assets $1.42 B
- Holdings in Top 10 50.0%
52 WEEK LOW AND HIGH
$184.04
$117.45
$194.06
Expenses
OPERATING RELATED FEES
- Expense Ratio 0.74%
SALES FEES
- Front Load N/A
- Deferred Load N/A
BROKERAGE FEES
- Turnover 32.92%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) $1,000,000
- IRA N/A
Fund Classification
-
Primary Theme
Health Care Sector Equity
- Fund Type Open End Mutual Fund
- Investment Style Health
FRBRX - Profile
Distributions
- YTD Total Return 17.4%
- 3 Yr Annualized Total Return 8.4%
- 5 Yr Annualized Total Return 8.0%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.12%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameFranklin Biotechnology Discovery Fund
-
Fund Family NameFranklin Templeton Investments
-
Inception DateMay 01, 2013
-
Shares Outstanding58392
-
Share ClassRetirement
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerEvan McCulloch
FRBRX - Performance
Return Ranking - Trailing
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 17.4% | -7.5% | 106.2% | 25.93% |
| 1 Yr | 49.3% | 8.3% | 128.7% | 6.21% |
| 3 Yr | 8.4%* | 0.1% | 38.7% | 79.02% |
| 5 Yr | 8.0%* | 0.4% | 30.0% | 77.70% |
| 10 Yr | 17.2%* | 8.9% | 20.1% | 27.64% |
* Annualized
Return Ranking - Calendar
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 24.2% | 3.8% | 63.8% | 28.97% |
| 2018 | -18.2% | -49.7% | 21.5% | 89.05% |
| 2017 | 16.6% | -59.8% | 54.4% | 54.81% |
| 2016 | -20.6% | -36.6% | 11.6% | 76.74% |
| 2015 | -2.4% | -62.4% | 27.9% | 63.11% |
Total Return Ranking - Trailing
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 17.4% | -7.5% | 109.2% | 25.93% |
| 1 Yr | 49.3% | 2.7% | 128.7% | 5.59% |
| 3 Yr | 8.4%* | 0.1% | 38.7% | 76.92% |
| 5 Yr | 8.0%* | 0.4% | 30.0% | 74.82% |
| 10 Yr | 17.2%* | 8.9% | 20.1% | 26.83% |
* Annualized
Total Return Ranking - Calendar
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 24.2% | 3.8% | 63.8% | 28.97% |
| 2018 | -18.2% | -25.3% | 22.2% | 90.51% |
| 2017 | 19.3% | -10.8% | 54.4% | 57.78% |
| 2016 | -16.8% | -36.6% | 11.6% | 69.77% |
| 2015 | 6.1% | -16.6% | 27.9% | 48.36% |
NAV & Total Return History
FRBRX - Holdings
Concentration Analysis
| FRBRX | Category Low | Category High | FRBRX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.42 B | 2.6 M | 48.7 B | 42.77% |
| Number of Holdings | 97 | 26 | 431 | 45.66% |
| Net Assets in Top 10 | 710 M | 670 K | 18.8 B | 26.01% |
| Weighting of Top 10 | 50.02% | 13.2% | 76.3% | 18.50% |
Top 10 Holdings
- Franklin IFT Money Market 9.85%
- Regeneron Pharmaceuticals Inc 6.91%
- Vertex Pharmaceuticals Inc 6.58%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Amgen Inc 5.71%
- Gilead Sciences Inc 5.04%
Asset Allocation
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| Stocks | 91.72% | 61.47% | 100.59% | 93.06% |
| Cash | 7.41% | -0.68% | 32.46% | 5.78% |
| Other | 0.87% | -3.06% | 6.07% | 21.97% |
| Preferred Stocks | 0.00% | 0.00% | 6.63% | 91.91% |
| Convertible Bonds | 0.00% | 0.00% | 0.03% | 91.91% |
| Bonds | 0.00% | 0.00% | 16.11% | 91.91% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.70% | 61.81% | 100.00% | 76.30% |
| Financial Services | 1.30% | 0.00% | 2.72% | 3.47% |
| Utilities | 0.00% | 0.00% | 0.00% | 91.33% |
| Technology | 0.00% | 0.00% | 20.28% | 94.22% |
| Real Estate | 0.00% | 0.00% | 6.03% | 91.91% |
| Industrials | 0.00% | 0.00% | 6.39% | 91.91% |
| Energy | 0.00% | 0.00% | 0.00% | 91.33% |
| Communication Services | 0.00% | 0.00% | 3.21% | 93.64% |
| Consumer Defense | 0.00% | 0.00% | 34.31% | 93.64% |
| Consumer Cyclical | 0.00% | 0.00% | 1.21% | 93.64% |
| Basic Materials | 0.00% | 0.00% | 2.61% | 95.38% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| US | 81.41% | 47.91% | 100.00% | 43.93% |
| Non US | 10.31% | 0.00% | 43.87% | 70.52% |
FRBRX - Expenses
Operational Fees
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.74% | 0.08% | 25.14% | 74.70% |
| Management Fee | 0.60% | 0.00% | 1.25% | 36.42% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | 0.15% | 0.03% | 0.40% | 77.50% |
Sales Fees
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 32.92% | 0.70% | 252.00% | 39.63% |
FRBRX - Distributions
Dividend Yield Analysis
| FRBRX | Category Low | Category High | FRBRX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 3.15% | 92.49% |
Dividend Distribution Analysis
| FRBRX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Net Income Ratio Analysis
| FRBRX | Category Low | Category High | FRBRX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.12% | -2.53% | 2.53% | 53.89% |
Capital Gain Distribution Analysis
| FRBRX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
FRBRX - Fund Manager Analysis
Managers
Evan McCulloch
Start Date
Tenure
Tenure Rank
Sep 15, 1997
23.06
23.1%
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Wendy Lam
Start Date
Tenure
Tenure Rank
Sep 01, 2018
2.08
2.1%
Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.
Akiva Felt
Start Date
Tenure
Tenure Rank
Jan 27, 2020
0.68
0.7%
Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.08 | 23.06 | 7.22 | 20.43 |
